Research and Markets: A Look at the Current Market Position for Eli Lilly within the Ethical Pharmaceutical Sector.DUBLIN Dublin, city, Republic of Ireland Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland Ireland, Irish Eire (âr`ə) [to it are related the poetic Erin and perhaps the Latin Hibernia], island, 32,598 sq mi (84,429 sq km), second largest of the British Isles. -- Research and Markets (http://www.researchandmarkets.com/reports/c33086) has announced the addition of Eli Lilly Eli Lilly can refer to:
This company analysis examines the current position and future outlook for Eli Lilly in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for key drugs. An interactive forecasting and analysis tool provides updated quantitative and qualitative information. Reasons to order your copy: --Benchmark Eli Lillys performance against key rivals in the ethical pharmaceutical sector --Understand why Eli Lilly is set to become the leading global CNS See Continuous net settlement. CNS See continuous net settlement (CNS). player by 2010 Topics Covered Chapter Executive summary Key findings Strategic outlook Current positioning: competitive outlook 2004 Strategic recommendations Key issues facing Eli Lilly: 2005-10 Eli Lilly's forecast revenue stream, 2005-10 In 2004, Lilly's generic risk stood at 16.4%. Despite significant therapy area-specific changes, total generic risk will remain low and broadly unchanged at 16.7% in 2010. Chapter 2 Global company strategy Introduction to Eli Lilly Assessment of strategic position Strengths Weaknesses Opportunities Threats Datamonitor's strategic recommendations Therapeutic foci Evolution of R&D focus Growth strategy assessment Organic growth Partnerships/licensing Mergers and acquisitions Chapter 3 Global portfolio and pipeline analysis Therapy area focus in 2004 Evolution of therapy area focus, 2004-10 Key growth drivers and resistors of future performance, 2005-10 Eli Lilly's CNS franchise Marketed products R&D compounds CNS portfolio sales forecasts and forecast revenue growth Diabetes and endocrinology endocrinology Medical discipline dealing with regulation of body functions by hormones and other biochemicals and treatment of endocrine system imbalances. In 1841 Friedrich Gustav Henle first recognized “ductless glands,” which secrete products directly into franchise R&D compounds Diabetes products sales forecasts and forecast revenue growth Eli Lilly's oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. franchise R&D compounds Oncology products sales forecasts and forecast revenue growth Eli Lilly's women's health Women's Health Definition Women's health is the effect of gender on disease and health that encompasses a broad range of biological and psychosocial issues. franchise Women's health portfolio sales forecasts and forecast revenue growth Infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. franchise Marketed products Infectious disease portfolio sales forecasts and forecast revenue growth Cardiovascular cardiovascular /car·dio·vas·cu·lar/ (-vas´ku-ler) pertaining to the heart and blood vessels. car·di·o·vas·cu·lar adj. Abbr. franchise Marketed products R&D compounds Cardiovascular portfolio sales forecasts and forecast revenue growth Eli Lilly's other products Marketed products Chapter 4 Us strategy, portfolio and pipeline US company strategy Introduction to Eli Lilly's presence in the US US marketing strategy US product sourcing strategy US portfolio and pipeline analysis US evolution of therapy area focus, 2004-10 Eli Lilly's CNS portfolio US sales forecasts and forecast revenue growth Eli Lilly's diabetes and endocrinology portfolio US sales forecasts and forecast revenue growth Eli Lilly's women's health portfolio US sales forecasts and forecast revenue growth Eli Lilly's oncology portfolio US sales forecasts and forecast revenue growth Eli Lilly's cardiovascular portfolio US sales forecasts and forecast revenue growth Eli Lilly's infectious disease portfolio US sales forecasts and forecast revenue growth Eli Lilly's 'other' portfolio US sales forecasts and forecast revenue growth Chapter 5 Corporate development Financial position, 2003-04 1 Revenue growth Historical assessment of Eli Lilly's profitability, 2000-04 Cost structure 2004 operating cost ratio benchmarking Business model clustering according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. 2004 cost ratios Liquidity, 2000-04 2004 growth and investment momentum Chapter 6 Appendix: supporting data Exchange rates List of Tables List of Figures For more information visit http://www.researchandmarkets.com/reports/c33086 Source: Datamonitor Datamonitor is a provider of online database and analysis services. The company is based in the United Kingdom and also has offices in the United States, Japan, and other countries.[1] The Datamonitor team includes analysts and professional researchers. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion